Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 12:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 6,732 matching trials from the live ClinicalTrials.gov search.
Conditions
Pain Management, Opioid Consumption
Interventions
Placebo, Oxycodone 5 mg, Multimodal Non-Opioid Analgesia
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Cancer, Dermatologic Conditions
Interventions
Quality of Life (QoL) Assessment
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
4
States / cities
Basking Ridge, New Jersey • East White Plains, New York • Hauppauge, New York + 1 more
Completed Not applicable Interventional Accepts healthy volunteers

Is Cryosurgery or Curettage More Effective at Treating Seborrheic Keratoses?

NCT01159860
Conditions
Seborrheic Keratosis
Interventions
cryosurgery, Curettage
Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Dementia
Interventions
Experimental: Intervention 1 (AB): Engagement in Motion-Based Activities (Wii & Magic Table), Experimental: Intervention 2 (BA): Engagement in Motion-Based Activities (Magic Table BA)
Other
Lead sponsor
Midwestern University
Other
Eligibility
21 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Downers Grove, Illinois
Completed Not applicable Interventional Results available

HIV-1, Insufficient Sleep and Vascular Endothelial Dysfunction

NCT04956861
Conditions
HIV-1
Interventions
Individualized Targeted Sleep
Behavioral
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
40 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boulder, Colorado
Conditions
Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory ALK-Positive Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Golcadomide, Leukapheresis, Positron Emission Tomography, Rituximab
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
Completed Phase 3 Interventional Results available

Study of AA4500 in the Treatment of Peyronie's Disease

NCT01221597
Conditions
Peyronie's Disease
Interventions
AA4500, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Homewood, Alabama • Phoenix, Arizona • Burbank, California + 25 more
Completed Not applicable Interventional

BMT Online Wellness Study

NCT03902210
Conditions
Bone Marrow Transplant
Interventions
Online Yoga, Podcast
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Healthy
Interventions
Rifampin, Canagliflozin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Human Gastrointestinal Physiology Data
Interventions
Glucotrol XL 5Mg Extended-Release Tablet, Glipizide ER 5 MG 24 HR Extended Release Oral Tablet, Rifaximin 200Mg Tab, 13C6-Glipizide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury

NCT06825143
Conditions
Metabolic Syndrome, Vascular Injury, Ischemic Preconditioning, Endothelial Function (reactive Hyperemia), Endothelial Dysfunction
Interventions
Ischemic preconditioning, Intravenous lactate infusion, No ischemic preconditioning (control), Normal Saline Infusion (Placebo), Ischemic preconditioning and intravenous lactate
Procedure · Drug · Combination Product
Lead sponsor
Gary Van Guilder
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Gunnison, Colorado
Conditions
Pediatric Surgical Patient
Interventions
oral oxycodone
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 6 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Suicide, Suicide, Attempted, Suicide and Self-harm, Suicide Threat
Interventions
Safe Alternatives for Teens and Youth - Parent (SAFETY-P), Treatment As Usual (TAU)
Behavioral
Lead sponsor
Jennifer Hughes
Other
Eligibility
10 Years to 18 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Columbus, Ohio
Conditions
Brain Death
Interventions
venous blood gas
Procedure
Lead sponsor
MemorialCare Health System
Other
Eligibility
1 Week and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Long Beach, California
Conditions
Heart Diseases
Interventions
Group 1 (Intervention), Group 2 (Control)
Behavioral
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years and older
Enrollment
2,420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
13
States / cities
Camden, New York • Canastota, New York • Carthage, New York + 10 more
Completed Not applicable Interventional Accepts healthy volunteers

Mobile Mindfulness Training for Smoking Cessation

NCT02037360
Conditions
Smoking Cessation
Interventions
Active Comparator App/Training, Experimental App/Training
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
1,251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Diabetes Mellitus, Type 2, Pre-diabetes, Obesity
Interventions
Lifestyle
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 50 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Infertility
Interventions
Observational
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
20 Years to 44 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Uveitis, Cystoid Macular Edema
Interventions
Pegaptanib
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Terminated Not applicable Interventional Accepts healthy volunteers

microRNA Testing for Identification of Personalized Weight Management

NCT04217850
Conditions
Overweight and Obesity, Weight Loss
Interventions
250 kcal Dietary Energy Restriction, Aerobic Exercise
Other
Lead sponsor
North Dakota State University
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Breast Cancer
Interventions
Fludarabine, Cyclophosphamide, Cyclosporine, Natural killer cells, IL-2, Methylprednisolone, Interleukin-2
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Combined Cognitive and Gait Training

NCT02362282
Conditions
Stroke
Interventions
Gait training, cognitive training, Arm training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Kidney Transplantation, Immunosuppression
Interventions
Tacrolimus Extended Release Oral Tablet [Envarsus], Mycophenolate Mofetil, Mycophenolic Acid Oral Product, Tacrolimus, Methylprednisolone, Prednisone, Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]
Drug
Lead sponsor
Simon Tremblay, PharmD, PhD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Cincinnati, Ohio
Recruiting No phase listed Observational

Multi-analyte Blood Test Clinical Trial

NCT05199259
Conditions
Liver Cirrhosis, Liver Cancer, HCC, Hepatocellular Carcinoma
Interventions
Multi-analyte Blood Test
Diagnostic Test
Lead sponsor
Helio Genomics
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Timeline
2022 – 2028
U.S. locations
7
States / cities
Escondido, California • Mission Hills, California • Gainesville, Florida + 4 more